MiniMed™ 780G® 对接受 MiniMed™ 770G® 治疗的 1 型糖尿病患者血糖管理、睡眠质量及心理状况的疗效：一项为期 3 个月的前瞻性单中心观察性研究。
Efficacy of MiniMed™ 780G® on glucose management, sleep quality, and psychological aspects in persons with type 1 diabetes treated with MiniMed™ 770G®: A 3-month prospective single-center observational study.
作者信息
Akiyama Tomoaki, Orime Kazuki, Akamatsu Ryoichi, Suezono Taichi, Akiyama Mako, Matsuura Arisa, Kaneko Ayano, Yamakawa Tadashi, Shinoda Satoru, Terauchi Yasuo
机构信息
Department of Endocrinology and Diabetes, Yokohama City University Medical Center, Yokohama, Japan.
Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan.
出版信息
J Diabetes Investig. 2026 Jan;17(1):165-173. doi: 10.1111/jdi.70198. Epub 2025 Nov 25.
AIMS/INTRODUCTION: The MiniMed™ 780G® is effective for improving glycemic control; however, few studies have specifically examined the impact of upgrading from MiniMed™ 770G® to MiniMed™ 780G® in adults. We determined the effects of upgrading from MiniMed™ 770G® to MiniMed™ 780G® (780G) on glucose management, psychological distress, daily life quality, and sleep in type 1 diabetes mellitus (T1DM).
MATERIALS AND METHODS
In this single-center prospective study, we observed 21 adults who transitioned from the MiniMed™ 770G® to the 780G for 3 months. Glycemic outcomes, insulin delivery parameters, frequency of alarms, and sensor calibrations were assessed. Patient-reported outcomes were evaluated using the Problem Areas in Diabetes (PAID), the Diabetes Treatment Satisfaction Questionnaire status version, the Diabetes Therapy-Related Quality of Life, and the Pittsburgh Sleep Quality Index.
RESULTS
Glycated hemoglobin (HbA1c) decreased (7.5 ± 1.3%-7.0 ± 0.8%, mean difference: -0.5%, 95% Confidence Interval (CI): -0.9 to -0.1; P = 0.018). Time in tight range (TITR) showed trends toward improvement (44.9 ± 15.5%-48.9 ± 15.5%, mean difference: 4.0%, 95% CI: -0.7 to 8.6; P = 0.090). Alarm frequency declined (11.9 ± 8.7-7.1 ± 5.5 times/day, mean difference: -4.8, 95% CI: -7.0 to -2.6; P = 0.0002), and calibration frequency decreased (3.6 ± 2.2-0.8 ± 0.6 times/day, mean difference: -2.8, 95% CI: -3.7 to -1.9; P < 0.0001). The PAID score improved, decreasing from 38.7 ± 19.9 to 31.7 ± 19.3 (mean difference: -7.0, 95% CI: -14.7 to 0.7; P = 0.074).
CONCLUSIONS
Favorable changes in HbA1c, TITR, and PAID scores suggest potential glycemic and psychological benefits.
目的/引言：美敦力780G胰岛素泵在改善血糖控制方面效果显著；然而，针对成人从美敦力770G胰岛素泵升级到美敦力780G胰岛素泵的影响，专门开展的研究较少。我们确定了从美敦力770G胰岛素泵升级到美敦力780G胰岛素泵（780G）对1型糖尿病（T1DM）患者血糖管理、心理困扰、日常生活质量和睡眠的影响。
材料与方法
在这项单中心前瞻性研究中，我们观察了21名从美敦力770G胰岛素泵转换至780G胰岛素泵并持续使用3个月的成年人。评估了血糖结果、胰岛素输注参数、警报频率和传感器校准情况。使用糖尿病问题领域（PAID）、糖尿病治疗满意度问卷现状版、糖尿病治疗相关生活质量以及匹兹堡睡眠质量指数对患者报告的结果进行评估。
结果
糖化血红蛋白（HbA1c）降低（从7.5±1.3%降至7.0±0.8%，平均差值：-0.5%，95%置信区间（CI）：-0.9至-0.1；P=0.018）。严格血糖控制时间（TITR）呈改善趋势（从44.9±15.5%升至48.9±15.5%，平均差值：4.0%，95%CI：-0.7至8.6；P=0.090）。警报频率下降（从每天11.9±8.7次降至7.1±5.5次，平均差值：-4.8，95%CI：-7.0至-2.6；P=0.0002），校准频率降低（从每天3.6±2.2次降至0.8±0.6次，平均差值：-2.8，95%CI：-3.7至-1.9；P<0.0001）。PAID评分有所改善，从38.7±19.9降至31.7±19.3（平均差值：-7.0，95%CI：-14.7至0.7；P=0.074）。
结论
HbA1c、TITR和PAID评分的有利变化表明可能对血糖和心理有益。
Zotero 插件